KROS Keros Therapeutics, Inc. - 8-K

Item 5.07     Submission of Matters to a Vote of Security Holders.

On June 3, 2026, Keros Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following three proposals: (1) to elect two nominees for director to hold office until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified (“Proposal 1”), (2) to ratify the selection by the Audit Committee of the Board of Directors of the Company (the “Board of Directors”) of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 (“Proposal 2”) and (3) to approve, on an advisory basis, the compensation of the Company’s named executive officers (“Proposal 3”) as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 22, 2026 (the “Proxy Statement”). Each of Proposal 1, Proposal 2 and Proposal 3 is described in detail in the Proxy Statement. The final results of the voting on each proposal are set forth below.

Proposal 1 – Election of Directors

The Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows:

Nominee

Votes For

Votes Withheld

Broker Non-Votes

Jean-Jacques Bienaimé

10,093,559.27

5,156,153

2,243,514

Charles Newton

14,716,598

533,114

2,243,514

Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026

The Company’s stockholders approved Proposal 2. The votes cast were as follows:

Votes For

Votes Against

Votes Abstain

16,708,279.27

783,953

994

There were no broker non-votes with respect to Proposal 2.

Proposal 3 – Advisory Vote on Executive Compensation

The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3. The votes cast were as follows:

Votes For

Votes Against

Votes Abstain

Broker Non-Votes

14,273,625.27

974,049

2,038

2,243,514